Last update 08 May 2025

PDE1 x SCNA

Basic Info

Related Targets
PDE1SCNA

Related

1
Drugs associated with PDE1 x SCNA
WX0005
Target
PDE1 x SCNA
Mechanism
PDE1 inhibitors [+1]
Active Org.
Harbin Pharmaceutical Group Co., Ltd.Harbin Pharmaceutical Group Co., Ltd.
Originator Org.
Harbin Pharmaceutical Group Co., Ltd.Harbin Pharmaceutical Group Co., Ltd.
Active Indication
Epilepsy
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with PDE1 x SCNA
CTR20200915
/ RecruitingPhase 1
随机双盲、安慰剂对照、剂量递增I期观察WX0005片的安全性、耐受性、药代动力学特征和食物影响
[Translation] A randomized, double-blind, placebo-controlled, dose-escalation phase I study to observe the safety, tolerability, pharmacokinetic characteristics, and food effects of WX0005 tablets
100 Clinical Results associated with PDE1 x SCNA
Login to view more data
100 Translational Medicine associated with PDE1 x SCNA
Login to view more data
0 Patents (Medical) associated with PDE1 x SCNA
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free